E UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit

: 1616

Examiner:

Serial No. : 10/722,737 Filed

: November 25, 2003

Inventors

: Bradley S. Galer : Arnold R. Gammaitoni

: Robert D. Dworkin

Title

: COMPOSITION AND METHOD

: FOR TREATING NEUROPATHIC

: SENSORY LOSS

Dated: March 20, 2007

Confirmation No.: 7300

35812

PATENT TRADEMARK OFFICE

Docket: BSG 021 US

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Petition Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

We submit herewith the usual Form PTO-1449 together with copies of publications listed therein. They are submitted to comply with the Applicant's duty of disclosure under 37 C.F.R. §1.56. Also enclosed is a copy of an International Search Report issued May 24, 2004. The enclosed publications are believed related in view of their mention in the Search Report for the reasons stated.

Applicants certify that each item of information contained in the Information Disclosure Statement was first cited in any communication from any foreign patent office in a counterpart foreign application not more than three months ago.

Also enclosed is the Credit Card Payment Form for the required fee of \$180.00. If, however, this amount is inadvertently not enclosed or is insufficient, the Commissioner is authorized to charge any insufficiency to Deposit Account No. 50-2656. This authorization is made in duplicate.

The Applicant(s) respectfully request(s) that this Information Disclosure Statement be officially entered into the file and that appropriate notification be made that it was considered by the Examiner.

03/26/2007 WABDELR1 00000056 10722737

03 FC:1806

180.00 OP

Respectfully submitted

Reg/No. 33,167

Attorney for Applicants

GTD:gi

(610) 558-9800

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/722,737		
Filing Date	11/25/2003		
First Named Inventor	Bradley S. Galer et al		
Art Unit	1616		
Examiner Name	George, Konata M.		
Attorney Docket Number	BSG 021 US		

Examiner	Cite	Cite No.1 Document Number Number-Kind Code ^{2 (ff known)}	Publication Date MM-DD-YYYY	T DOCUMENTS		
Initials*	No.1			Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		^{US-} 5,688,830	11-18-1997	Berger et al		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-		-		
		US-				
-		US-				
		US-				
		US-				
	-	US-		-		
		US-	 			
		US-			 	
		US-	 			
		US-	 		 	
		US-	 			
		US-	 			

		FORE	IGN PATENT DOCU	MENTS		
	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Γ
	<u> </u>	Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Office Document	Or Relevant Figures Appear	T⁵
	ļ	JP 59093018	05-29-1984	Kadota Tatatomi		
	ļ					
 .						
	-	•				
	<u> </u>	<u> </u>			}	

Committee			
Examiner		Date	
Signature			1
Oignature		Considered	1
*EVALUED	* 	1	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/722,737 Filing Date 11/25/2003

INFORMATION DISCLOSURE STATEMENT BY APPLICANT **First Named Inventor** Bradley S. Galer et al/ Art Unit 1616 (Use as many sheets as necessary) **Examiner Name** George, Konata M. Sheet 12 2 Attorney Docket Number of **BSG 021 US**

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS	
Initials*	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Escobar P L et al: "Teres Minor. Source of Symptoms Resembling Ulnar Neuropathy or C8 Radiculopathy, Am J of Physical Med & Reh, 1988, Vol. 67, No. 3, pgs 120-122	
		Carlissi P T et al: "Peripheral Diabetic Neuropathy: Current Concepts in Treatment", Annals of Pharmacotgherapy, Jul/Aug 1995, Vol. 29, No. 7/8, pgs 769-777	
		Devers A et al: "Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study", Clin. Jour. of Pain, Sep 2000, Vol. 16, No. 3, pgs. 205-208	
			
·			

Examiner	Date
Signature	Considered
REVANIATED. In Walter of	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.